2020 commercialisation, page-443

As a LT substantial holder (3mill +) I await the Oct 4C with trepidation. I have used SleepCheck and have come to the conclusion that as a screening device only it has limited commercial value. Once the initial rush is over I think it will wither on the vine and the next 4C will probably have the best figured we are likely to see. With ResAppdx we are completely at the mercy of the medical fraternity as to whether they use the device in their Telehealth consultations. If the 4C shows low revenue levels I can’t see things ever improving considering the past 6 months have given us the best conditions for Telehealth we are also ever likely to see. What Rap have developed is truly remarkable but if the public are not prepared to buy it then it is worthless. The 4C will give us an excellent indication whether I am right or wrong.